文献速递生殖医学

17α-羟孕酮血清水平对精子参数异常患者促卵泡激素反应性的预测作用

Predictive role of 17α-hydroxy-progesterone serum levels of response to follicle-stimulating hormone in patients with abnormal sperm parameters.
PubMed 文献 · Fertil Steril · 2023-09-23

前瞻性队列研究纳入50例特发性精子参数异常且促性腺激素和总睾酮正常的患者,皮下注射FSH 150 IU每周3次共3个月。治疗后精子浓度、总精子数、前向运动、正常形态百分比、FSH、总睾酮及睾丸体积均显著增加;治疗前17αOH-P水平与精子浓度、总精子数、前向运动及正常形态的增幅呈负相关,与精子细胞增幅呈正相关。17αOH-P<1.18 ng/mL可预测精子浓度翻倍(敏感度90.0%、特异度73.3%)和总精子数翻倍(敏感度91.3%、特异度81.48%)。

要点

  • FSH 150 IU每周3次皮下注射3个月后,精子浓度、总精子数、前向运动、正常形态百分比、FSH、总睾酮及睾丸体积均显著增加。
  • 治疗前17αOH-P水平与治疗后精子浓度、总精子数、前向运动及正常形态的增幅呈负相关,与精子细胞增幅呈正相关。
  • 17αOH-P<1.18 ng/mL预测精子浓度翻倍的敏感度90.0%、特异度73.3%,预测总精子数翻倍的敏感度91.3%、特异度81.48%。

核心结论

  • 治疗前血清17αOH-P水平似乎能够预测外源性FSH皮下给药后精子生成改善的成功与否。
  • ROC曲线提示17αOH-P<1.18 ng/mL可预测特发性精子参数异常且促性腺激素正常患者接受外源性FSH后精子浓度和总精子数翻倍。

研究设计与样本

  • 前瞻性队列研究,在大学附属生育中心开展。
  • 纳入50例少精子症、弱精子症和/或畸形精子症且促性腺激素和总睾酮血清水平正常的患者。
  • 干预为外源性FSH皮下注射150 IU每周3次,连续3个月。

主要发现

  • 治疗后精子浓度、总精子数、前向运动、正常形态百分比、FSH水平、总睾酮水平及睾丸体积均显著增加。
  • 治疗前17αOH-P水平与治疗后精子浓度、总精子数、前向运动及正常形态的增幅呈负相关,与精子细胞增幅呈正相关。
  • 17αOH-P<1.18 ng/mL预测精子浓度翻倍的敏感度为90.0%、特异度为73.3%。
  • 17αOH-P<1.18 ng/mL预测总精子数翻倍的敏感度为91.3%、特异度为81.48%。

关键数值与推荐

  • 以FSH给药结束时精子浓度翻倍定义为阳性结局。
  • 17αOH-P<1.18 ng/mL预测精子浓度翻倍:敏感度90.0%,特异度73.3%。
  • 17αOH-P<1.18 ng/mL预测总精子数翻倍:敏感度91.3%,特异度81.48%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To study the possible role of serum 17α-hydroxy-progesterone (17αOH-P) levels in predicting favorable responses to follicle-stimulating hormone (FSH) administration in patients with normal serum FSH levels and idiopathic abnormal sperm parameters. DESIGN: Prospective cohort study. SETTING: University-affiliated fertility center. PATIENTS: Fifty patients with oligozoospermia, asthenozoospermia, and/or teratozoospermia and normal serum levels of gonadotropins and total testosterone (TT). INTERVENTION: Treatment with exogenous FSH is administered subcutaneously at a dose of 150 IU 3 times a week for 3 consecutive months. MAIN OUTCOME MEASURE(S): Luteinizing hormone levels, FSH levels, TT levels, 17αOH-P levels, testicular volume, conventional sperm parameters, and seminal spermatid concentration were evaluated before and after therapy. To evaluate the predictive role of pretreatment serum 17αOH-P levels on FSH responsiveness, the doubling of sperm concentration at the end of the FSH administration was considered a positive outcome. RESULTS: After therapy, patients showed a significant increase in sperm concentration, total sperm count (TSC), progressive motility, percentage of normal forms, FSH levels, TT levels, and testicular volume. There was a negative correlation between pretreatment 17αOH-P levels and the posttreatment increase in sperm concentration, TSC, progressive motility, and normal morphology, and a positive correlation with the posttreatment increase in spermatids. Predictive analysis showed that 17αOH-P levels (<1.18 ng/mL) foretold a doubling of sperm concentration with a sensitivity of 90.0% and a specificity of 73.3%, and of TSC with a sensitivity of 91.3% and a specificity of 81.48%. CONCLUSION: The results of this study suggest that pretreatment serum levels of 17αOH-P, a marker of steroidogenic function, appear to be able to predict the success of subcutaneous administration of exogenous FSH in terms of spermatogenesis improvement. Receiver operating characteristic curves indicated that 17αOH-P levels (<1.18 ng/mL) predict a doubling of sperm concentration and TSC after exogenous FSH administration to patients with idiopathic abnormal sperm parameters and normal gonadotropin levels.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Cannarella R, Condorelli RA, Gusmano C, et al. Predictive role of 17α-hydroxy-progesterone serum levels of response to follicle-stimulating hormone in patients with abnormal sperm parameters. Fertil Steril. 2023. PMID: 37748551. doi:10.1016/j.fertnstert.2023.09.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。